Evidence map›Paper›PMID 40374728›Full record

ArticleScientific reports2025

Low expression of miR-7-5p promotes resistance to radiotherapy in lung cancer through direct upregulation of PKP2 expression.

Fan Zhang, Jiaxue Yang, Xiao-Lu Qiu, Jie He, Chun Cheng, Yi Sang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Human mutation · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fan Zhang *Department of Respiratory, Jiangxi Provincial Children's Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Jiaxue Yang *Department of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xiao-Lu Qiu *Department of Children Health, Jiangxi Provincial Children's Hospital, Nanchang University, Nanchang, Jiangxi, China.
Jie HeJiangxi Key Laboratory of Oncology, Department of Center Laboratory, The Third Affiliated Hospital of Nanchang University (The First Hospital of Nanchang), Nanchang, 330008, China.
Chun ChengJiangxi Key Laboratory of Oncology, Department of Center Laboratory, The Third Affiliated Hospital of Nanchang University (The First Hospital of Nanchang), Nanchang, 330008, China. chunchun1990h@163.com.
Yi SangJiangxi Key Laboratory of Oncology, Department of Center Laboratory, The Third Affiliated Hospital of Nanchang University (The First Hospital of Nanchang), Nanchang, 330008, China. ndsfy001889@ncu.edu.cn.

Funding

Jiangxi Key Laboratory 2024SSY06042Jiangxi Provincial Natural Science Foundation of China 20212ACB216013Nanchang Natural Science Foundation of China 2021-129the Special Fund for the Natural Science Foundation of China 8216110654
6 · The paper itself

Abstract

Lung cancer remains a significant global health challenge, with advanced stages often limiting surgical options and necessitating systemic therapies, such as radiotherapy. Resistance to radiotherapy frequently undermines the treatment efficacy. This study explored the role of miR-7-5p in modulating the expression and radiosensitivity of plakophilin-2 (PKP2) in non-small cell lung cancer (NSCLC). Using clonogenic assays, CCK-8 assays, immunofluorescence staining, western blotting, and reporter gene assays, we assessed the effects of miR-7-5p overexpression and inhibition on A549 NSCLC cells. The results show that miR-7-5p overexpression enhanced radiosensitivity by increasing DNA damage (evidenced by higher γ-H2AX foci) and inhibiting non-homologous end joining (NHEJ) repair. Bioinformatic and experimental validation identified PKP2 as a direct target of miR-7-5p. PKP2 overexpression mitigated the radiosensitizing effects of miR-7-5p, confirming the miR-7-5p/PKP2 axis's role in regulating radiosensitivity. This study highlights the potential of targeting the miR-7-5p/PKP2 pathway to overcome radiotherapy resistance in NSCLC and offers a promising therapeutic approach to enhance treatment outcomes.

Indexed as

Carcinoma, Non-Small-Cell LungGene Expression Regulation, NeoplasticLung NeoplasmsMicroRNAsPlakophilinsRadiation ToleranceA549 CellsCell Line, TumorDNA DamageDNA End-Joining RepairHumansUp-RegulationMicroRNAsMIRN7-1 microRNA, humanPKP2 protein, humanPlakophilinsMiR-7-5pNSCLCPKP2Radiotherapy

Identifiers

PMID40374728
PMCPMC12081904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.